{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:04:04Z","timestamp":1784891044062,"version":"3.55.0"},"reference-count":8,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Venetoclax is a selective inhibitor of BCL2. While its combination with hypomethylating agents (HMAs) is associated with manageable side effects, thyroid dysfunction has not been previously reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Report<\/jats:title>\n                    <jats:p>We present the case of a 62-year-old female with relapsed\/refractory AML who was treated with azacitidine and venetoclax. Within a month, she developed hypothyroidism with elevated TSH (42.86 \u00b5IU\/mL) and low FT4 (0.34 ng\/dL). Baseline thyroid function tests were normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management &amp; Outcome<\/jats:title>\n                    <jats:p>Ultrasonography showed a diffusely enlarged thyroid gland, and thyroid autoantibodies were negative, ruling out autoimmune thyroiditis.Thyroid hormone replacement therapy was initiated, normalizing thyroid function, while venetoclax was continued due to its efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case highlights a rare, non-autoimmune thyroid dysfunction associated with venetoclax. The absence of autoantibodies suggests a mechanism unrelated to autoimmunity, emphasizing the need for thyroid monitoring during venetoclax therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251331601","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T02:12:46Z","timestamp":1744596766000},"page":"1011-1013","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Venotoclax associated hypothyroidism in a patient with acute myeloid leukemia"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6316-5369","authenticated-orcid":false,"given":"U\u011fur","family":"Can \u0130zlimek","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Cukurova Medical School, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-4622","authenticated-orcid":false,"given":"Bar\u0131\u015f","family":"Karag\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Diseases, Cukurova Medical School, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"G\u00fcrkan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cukurova Medical School, Adana, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2018.09.001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"e_1_3_2_4_2","unstructured":"3. Venetoclax with Azacitidine Drains Fuel from AML Stem Cells Daisuke Nakada1 * 1Department of Molecular & Human Genetics Baylor College of Medicine Houston TX 77030 USA."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Jannina A Penelb N Ladsousa M et al. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit. Rev. Oncol. Hematol. 2019; 141: 23\u201335.","DOI":"10.1016\/j.critrevonc.2019.05.015"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.084145"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2018.18"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251331601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251331601","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251331601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:59Z","timestamp":1777689059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251331601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552251331601"],"URL":"https:\/\/doi.org\/10.1177\/10781552251331601","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]}}}